Skip to Content
US Videos

2 Undervalued Biotechs Vying for a Big Market

Gilead and Intercept are both developing drugs aimed at a $10 billion market opportunity in liver-disease treatment, but they present different considerations for biotech investors.

Mentioned: ,

Stefan Quenneville: We recently put out a report on the therapeutic area of NASH. NASH stands for nonalcoholic steatohepatitis, which is really just a fancy way of saying fatty liver disease.

So, what is NASH? NASH is a very common but severe liver disease closely related to obesity and diabetes that has really no viable treatments currently.

Stefan Quenneville, CFA does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.